Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 12.00
+0.50 (4.35%)
At close: Mar 25, 2026
Fusion Antibodies Market Cap
Fusion Antibodies has a market cap or net worth of 15 million as of March 25, 2026. Its market cap has increased by 126.60% in one year.
Market Cap
15.00M
Enterprise Value
15.14M
Revenue
1.60M
Ranking
n/a
PE Ratio
n/a
Stock Price
12.00
Market Cap Chart
Since December 18, 2017, Fusion Antibodies's market cap has decreased from 27.28M to 15.00M, a decrease of -45.01%. That is a compound annual growth rate of -6.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 25, 2026 | 15.00M | -5.71% |
| Dec 31, 2025 | 15.91M | 135.22% |
| Dec 31, 2024 | 6.76M | 167.72% |
| Dec 29, 2023 | 2.53M | -78.42% |
| Dec 30, 2022 | 11.71M | -59.09% |
| Dec 31, 2021 | 28.62M | -9.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 18, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Poolbeg Pharma | 30.14M |
| Arecor Therapeutics | 25.49M |
| ImmuPharma | 24.63M |
| Sareum Holdings | 21.40M |
| Aptamer Group | 18.88M |
| SkinBioTherapeutics | 16.20M |
| Genflow Biosciences | 10.58M |
| Oxford BioDynamics | 9.23M |